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Abstract
Background: Whilst evidence suggests cognitive behaviour therapy (CBT) may be effective for depressed older
people in a primary care setting, few studies have examined its cost-effectiveness. The aim of this study was to
compare the cost-effectiveness of cognitive behaviour therapy (CBT), a talking control (TC) and treatment as usual
(TAU), delivered in a primary care setting, for older people with depression.
Methods: Cost data generated from a single blind randomised controlled trial of 204 people aged 65 years or
more were offered only Treatment as Usual, or TAU plus up to twelve sessions of CBT or a talking control is
presented. The Beck Depression Inventory II (BDI-II) was the main outcome measure for depression. Direct
treatment costs were compared with reductions in depression scores. Cost-effectiveness analysis was conducted
using non-parametric bootstrapping. The primary analysis focussed on the cost-effectiveness of CBT compared with
TAU at 10 months follow up.
Results: Complete cost data were available for 198 patients at 4 and 10 month follow up. There were no
significant differences between groups in baseline costs. The majority of health service contacts at follow up were
made with general practitioners. Fewer contacts with mental health services were recorded in patients allocated to
CBT, though these differences were not significant. Overall total per patient costs (including intervention costs)
were significantly higher in the CBT group compared with the TAU group at 10 month follow up (difference £427,
95% CI: £56 - £787, p < 0.001). Reductions in BDI-II scores were significantly greater in the CBT group (difference
3.6 points, 95% CI: 0.7-6.5 points, p = 0.018). CBT is associated with an incremental cost of £120 per additional
point reduction in BDI score and a 90% probability of being considered cost-effective if purchasers are willing to
pay up to £270 per point reduction in the BDI-II score.
Conclusions: CBT is significantly more costly than TAU alone or TAU plus TC, but more clinically effective. Based
on current estimates, CBT is likely to be recommended as a cost-effective treatment option for this patient group if
the value placed on a unit reduction in BDI-II is greater than £115.
Trial Registration: isrctn.org Identifier: ISRCTN18271323
Background
Depression in older people is common, frequently
missed and undertreated [1]. Within the community it
often becomes a chronic disorder with up to 74% of
people remaining depressed one year after detection [2].
Depression is associated with an increase in the use of
hospital and outpatient medical services [3-5], even after
adjustments have been made for demographic, socioeco-
nomic and functional status, and co-morbidity [5-7]
Depressed patients are also more likely to end up in
nursing homes [8]. All of this places an increased
demand on health and social care resources [9] of which
older people are traditionally high users.
Cognitive Behaviour Therapy (CBT) is a clinically
effective and recommended treatment for depressive dis-
order in adults of all ages and is associated with
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continued improvement over time [10]. Older people in
particular tend to be high utilisers of medical services
and service demands increase with clinical depression
[7,11]. CBT is effective for depressed older people in a
primary care setting [12]. However, few studies have
assessed whether psychological interventions such as
CBT are cost effective for depressed older people treated
in a primary care setting.
Bower et al (2000) conducted an analysis of the cost-
effectiveness of CBT for depression in people of all ages,
comparing CBT with non-directive counselling and
usual general practitioner care [13]. Both non-directive
counselling and CBT were associated with a reduction
in depressive symptoms at four months, but this was
not sustained through till 12 months follow up. There
were no significant differences in direct costs (drugs,
outpatient services, inpatient services, protocol therapy,
travel costs), production losses, or societal costs between
the three treatments at either four or 12 months. How-
ever, closer analysis of the data showed patients receiv-
ing usual general practitioner care alone recorded more
GP consultations, greater use of antidepressants, and
more psychiatric referrals. Unützer et al (2000) rando-
mised 1,801 depressed primary care patients aged over
60 to usual care by their primary care doctor or colla-
borative care. The cost of the intervention was about
£370 ($670; €550) per patient over 12 months which
was substantially less than a year’s worth of anti-demen-
tia drugs (approximately £1,000) [14].
We present a cost-effectiveness analysis based on a
randomised controlled trial of three treatments, Treat-
ment as Usual (TAU), TAU plus CBT or TAU plus a
talking control, for older people with depression pre-
senting in primary care [12]. This design was used to
balance known and unknown factors which may predict
outcome and aimed to take into account the effects of
“non-specific” factors in therapy, including face-to-face
contact with another person, warmth and empathy. For
the purpose of this paper we will refer to the three
interventions as TAU, CBT or TC, while acknowledging
the latter two were provided in addition to TAU.
Aims
Health Economics Objective
First, to compare the average costs of care associated
with CBT, a Talking Control (TC) or Treatment as
Usual (TAU) for older people with depression. Secondly,
to estimate the cost-effectiveness of CBT plus TAU
compared with TAU alone for older people with depres-
sion using the change in Beck Depression Inventory-II
(BDI-II) score at the trial end point. The analysis was
conducted from the perspective of the UK Departments
of Health and Social Services.
Methods
The study was conducted in a primary care setting in
North London between April 2004 and September 2007.
The inclusion criteria were (1) a primary diagnosis of
depressive disorder obtained from the Geriatric Mental
State and History and Etiology Schedule [15]. (2) a score
of 14 or higher on the BDI-II [16] (3) sufficient com-
mand of English to use CBT techniques; and (4) if tak-
ing an antidepressant, a stable dose of medication for at
least 8 weeks prior to randomization. Informed consent
was obtained from all participants. Full details on the
design and methods employed in the clinical trial, which
adhered to the CONSORT guidelines, have been
reported in Serfaty et al, (2009) [12].
The intervention
Patients allocated to CBT or TC were offered up to
twelve sessions with a therapist accredited by the British
Association of Behavioural and Cognitive Psychothera-
pists. Within the constraints of the number of sessions
available, the patient and the therapist collaboratively
agree when therapy should terminate. The TC was used
to control for the main non-specific effects of therapy,
and is most comparable to a befriending service. All
patients received usual care as managed by their general
practitioner. The project was approved by the ethics
committee of Camden and Islington Community Health
Services Trust and supported by the North Central Lon-
don Research Consortium, LREC reference 03/37.
Health service utilisation
Data on health service use was accessed via general
practice medical records and collected using a modified
version of the Client Service Receipt Inventory (CSRI)
[17]. Data were collected for three month periods prior
to all follow up points: baseline, 4 month post baseline
and 10 month post baseline.
Direct treatment costs associated with the interven-
tion, as well as community health service costs were
included. Community health care included contacts with
GP’s, practice and district nurses, health visitors, psy-
chiatrists, clinical psychologists, occupational therapists,
physiotherapists, community psychiatric nurses and gen-
eral counsellors. All prescribed medication was
recorded. Data specifically for antidepressant medication
is provided in detail in Serfaty et al (2009) [12]. No sig-
nificant differences at baseline or during the course of
the trial were observed and imipramine dose equivalents
were similar in all 3 groups. Data relating to collecting
of prescriptions or medication compliance were not
available. However, as antidepressant prescribing was
similar across groups, it is likely that the costs of medi-
cation were balanced.
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Although it would have been helpful to obtain informa-
tion on indirect costs such as production losses, patient
time, and caregiver time and burden, this was not possi-
ble for ethical reasons. The bulk of the CSRI was col-
lected through consultation with GP records. Inclusion
of other costs would have entailed further data collection
from a vulnerable group of patients already burdened
with having to complete a number of rating scales.
The authors believed there was no reason why CBT
should affect the use of acute hospital care services, and
moreover, there was concern that any underlying differ-
ences in functionality between patient groups may result
in differences in hospital utilisation, and therefore intro-
duce unnecessary variance to the costs. While there was
no rationale for including hospital utilisation in the ana-
lysis, these data were available and provided an opportu-
nity to assess the reasons for admission and whether the
decision to exclude these costs was appropriate.
Unit costs
Costs are presented from the perspective of the UK
Departments of Health and Social Services, in 2008
values (Table 1). Patient-level costs were calculated by
multiplying frequency of contacts with health service
providers with unit costs from Unit Costs of Health and
Social Care 2008 [18]. Intervention costs were based on
the number of sessions attended by each patient. Data for
the number of therapy sessions was continuous and nor-
mally distributed and therefore tested using an unpaired
t-test. There was no significant difference between the
mean number of sessions attended for CBT (mean [SD],
7.09 [4.41] sessions) or TC (mean [SD], 7.58 [4.56] ses-
sions) (p = 0.52). Total costs are presented as a cumula-
tive total of health service costs and intervention costs.
Statistical Analysis
Although detailed resource use data were collected, the
sample size was calculated on the basis of expected clin-
ical outcomes and not on the cost analysis and reported
in Serfaty et al [12]. The cost analysis was based on
patients with complete cost-data only, given very little
was missing (n = 6/204, 3%). As costs were not normally
distributed, analysis of variance (ANOVA) was per-
formed on log-transformed cost data. As data had only
been collected for three months prior to each follow up
period (at 4 and 10 months), the ‘gaps’ were estimated
as a proportion of the costs incurred during the subse-
quent follow up periods. The primary analysis was of
total costs at the trial end point (10 months), but we
also report costs at 4 months follow up. A sub-analysis
was conducted for mental health services using a chi-
squared test (including visits to psychiatrists, clinical
psychologists, occupational therapists, community psy-
chiatric nurse and counsellors). Around 90% of patients
did not use any mental health services, therefore neither
a t-test, nor a non-parametric test such as Kruskall
Wallis, could be used on the continuous variable “num-
ber of contacts”, hence the variable was dichotomised.
Baseline costs were examined for differences between
groups, but were not used to adjust the results.
Effectiveness was defined as the change in BDI-II from
baseline to follow up. As there were no significant differ-
ences between groups on health-related quality of life, we
did not perform a cost-effectiveness analysis using this
outcome measure. Multiply-imputed values generated for
the effectiveness analysis (Serfaty et al., 2009) were used in
the case of missing BDI-II follow-up values. Outcomes
data were missing for 13% and 18% of the patients at 4
and 10 months respectively, with no difference across
arms. We based our analysis on the imputed outcomes
data used for the effectiveness trial [12]. Outcomes were
imputed using multiple imputation [19], using the ice
command in STATA to generate 5 sets of imputed values.
Cost-effectiveness analysis
We performed an incremental cost-effectiveness analysis
(CEA) comparing CBT with both TC and TAU, calcu-
lating the incremental cost-effectiveness ratios (ICER), i.
e. the difference in average costs divided by the differ-
ence in average effects between groups. In order to
Table 1 Unit Costs (£ 2008)
Community
Health
Services
Unit
Cost
Reference
(PSSRU Unit Costs 2008)
GP contact 36 Per clinic consultation lasting 11.7 minutes
Phoned GP for
advice
22 phone call 7.1 mins
GP home visits 58 home visit 23.4 mins
Practice nurse 11 Per consultation
Phoned practice
nurse
6.72 data not available. set as a proportion
according to GP time consult: phone visit
District nurse 26 Per home visit
Health Visitor 16.5 £33 per hour inc quals; Assume 30 mins
session.
Psychiatrist 106 Per contract hour
Clinical
psychologist
41 Per professional chargeable hour.
Occupational
Therapist
66 Average cost for a one to one contact.
Physiotherapist 42 Average cost for a one to one contact.
Community
Psychiatric nurse
32 Nurse specialist (community). Per hour
(including qualifications)
Counsellor/Indiv
Therapist
40 Per hour of client contact. Counselling
services in primary medical care.
Intervention
costs
CBT session 66 CBT session
Talking control
session
24 Social worker assistant
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capture the uncertainty around the estimates, 1000 non-
parametric bootstrap replications were generated from
the sets of multiply imputed data, and mean cost and
effect were plotted in a cost effectiveness plane.
As we do not know the threshold willingness to pay
value for additional effectiveness associated with CBT,
the probability that CBT will be considered cost effective
was calculated for a range of threshold values and pre-
sented in a cost effectiveness acceptability curve (CEAC).
Data were analysed and prepared in Stata Version 11
(Stata Corp, College Station, Tex.), and bootstrapping and
cost-effectiveness analysis was undertaken in MS Excel.
Our a priori hypothesis aimed to compare costs in rela-
tion to our main outcome measure, the BDI-II. Serfaty
et al (2009) did not find any significant difference in Euro-
qol scores between groups at any time point (change in
EQ-5D from baseline to follow -up: 0.04 CBT; 0.06 TAU)
[12]. A cost-effectiveness analysis on our subsidiary out-
come measure would therefore not be appropriate.
Results
Recruitment and follow through
Of the 204 participants who entered the study, 83 (40.7%)
self referred, 72 (35.3%) were referred by their GP and 49
(24.0%) were recruited through GP data bases. The major-
ity were female (n = 162; 79.4%), white (n = 154; 75.5%)
and aged 74.1(SD 7.0) years. One hundred and fifty
(73.5%) were antidepressant free at baseline. There were
no differences in any of the above characteristics in those
allocated Treatment as Usual (TAU), TAU plus CBT (n =
70), or TAU plus a Talking Control (n = 67). The avail-
ability of cost data was high. Among 204 patients recruited
into the trial, 198 patients had complete cost data at 10
months follow up (post baseline). Six cases were missing
having all withdrawn from the trial after baseline.
Health service utilisation
The majority of community health service contacts were
made with general practitioners (85%). Overall, the aver-
age number of contacts were very similar between CBT
and TAU groups, and lowest in the TC group (Table 2).
Significant differences are tested below in the section on
average costs, where resource counts are multiplied by
unit costs.
Mental health service use
Patients in the CBT group generally reported fewer con-
tacts with mental health services than patients in other
groups (Table 3). Patients in the TAU group recorded
the highest average number of contacts. However, there
were no statistically significant differences in the pro-
portion of patients who had at least one contact with
mental health services at either follow up point (four
months post-baseline: CBT 8.96%, TC 7.69%, TAU
16.67% p = 0.207; 10 months post-baseline CBT 11.94%,
TC 12.31%, TAU 13.64% p = 0.953). As the numbers of
patients accessing mental health services was very small
(ten or less in each group), it may not have been possi-
ble to detect meaningful differences between the treat-
ment groups.
Hospitalisation and reasons for admission
The reasons for hospital admission were varied,
although the majority were unplanned emergency
admissions that were unlikely to have been influenced
by the psychological interventions (e.g. orthopaedic sur-
gery). Only one hospital admission was related to
depression. Outpatient appointments were also unre-
lated to depression. The number of inpatient admissions
did not differ across arms, or over time (overall propor-
tion of admissions: baseline 12%, four months: 10%, 10
months: 13%). These findings supported the decision to
exclude hospital costs from the analysis as they would
have only introduced a source of unwanted variation to
the costs data.
Average Costs
Mean per patient costs are shown in Table 4 by treat-
ment group. Histograms showed cost data was highly
skewed, therefore tests of significance using one way
ANOVAs were performed on log-transformed data.
Results showed no significant difference between groups
in baseline costs (p = 0.0703). No difference in commu-
nity health service costs were shown at either four or 10
Table 2 Average number of contacts with community
health services (over both follow up periods)
CBT
n = 67
TC
n = 65
TAU
n = 66
Total
n = 198
GP contacts 6.97 6.08 7.17 6.74
Phoned GP for advice 0.28 0.49 0.59 0.45
GP home visits 2.91 1.35 2.14 2.14
Practice nurse 3.10 1.92 2.95 2.67
Phoned practice nurse 0.10 0.22 0.05 0.12
District nurse 2.88 0.40 2.92 2.08
Health Visitor 0.00 0.00 0.00 0.00
Physiotherapist 0.55 0.72 1.11 0.79
Table 3 Average number of contacts with mental health
services (over both follow up periods)
CBT TC TAU Total
Mental health services:
Psychiatrist 0.09 0.09 0.11 0.10
Clinical psychologist 0.21 0.60 0.35 0.38
Occupational Therapist 0.03 0.05 0.18 0.09
Community Psychiatric nurse 0.00 0.09 0.08 0.06
Counsellor/Therapist 0.27 0.00 0.47 0.25
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months follow up. However, total per patient costs
(including intervention costs) were significantly higher
in the CBT group compared with the TAU group at
both four months (difference £380, 95% CI: £254, £311,
p < 0.001) and 10 months follow up (difference £427,
95% CI: £56, £787, p < 0.001). Overall, total per patient
costs were lowest in the TC group.
Figure 1 demonstrates how there is very little differ-
ence between groups in community health service costs.
The high total cost of CBT is being driven by the cost
of the intervention (£437, in comparison with £0 for
TAU), and a relatively higher spend on community
health services (£1027, in comparison with £704 for
TC). CBT patients may be encouraged to seek help for
their physical health problems, which incurs increased
health contacts.
Effectiveness
Effectiveness was assessed using the Beck Depression
Inventory-II. Intent to treat (ITT) analysis found a -3.07
(95% CI, -5.73, -0.42) and -3.65 (-6.18, -1.12) improve-
ment in BDI-II score in favour of CBT against TAU and
TC respectively [12]. These findings were confirmed
with complier’s average causal effect (CACE) analysis,
adjusted for BDI-II, which showed the benefit of CBT as
0.40 of a BDI-II point (95% CI: 0.01-0.72) per therapy
session. Reductions in BDI-II scores were significantly
greater in the CBT group at four months and 10
months follow up compared with both the TAU group
and the TC groups (Table 5). Twenty two (11%) and 31
(16%) patients did not complete the 4 and 10 months
BDI-II questionnaire, respectively, and their outcome
was imputed by multiple imputation. Euroqol data
Table 4 Mean per patient costs (£) by group (SD)
CBT
n = 67
TC
n = 65
TAU
n = 66
p value
Baseline Costs (3 months) 180 (127) 163 (125) 225 (193) 0.0703
Intervention costs 437 (276) 180 (102) - 0.0000
Community health service costs at 4 months 304 (312) 240 (199) 361 (340) 0.1604
Community health service costs at 10 months 1027 (1118) 704 (523) 1037 (1005) 0.0733
Total costs at 4 months 741 (437) 419 (206) 361 (340) 0.0000
Total costs at 10 months 1464 (1198) 884 (537) 1037 (1005) 0.0001
*costs cannot be equated to the average numbers of contacts reported above, as they have been extrapolated to estimate the gaps in between follow up
periods.
437
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0
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Figure 1 Average costs, by treatment group.
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showed no significant differences by intervention group,
with a 0.05 points (95% CI, -0.04, 0.14) higher increase
at 4 months for CBT compared to TAU, and 0.04 (95%
CI, -0.05, 0.12) for CBT against TC [12].
Cost-effectiveness
At both four and 10 months follow up, CBT was more
costly, and more effective than TAU and TC. Dividing
these incremental costs by the incremental effectiveness
allows us to estimate the incremental cost-effectiveness
ratio (ICER) for CBT compared to TAU (Table 6) and
TC (Table 7), at both follow up points. Our primary
analysis was the cost-effectiveness of CBT compared
with TAU at trial end point, being 10 months. In this
case, CBT was associated with an ICER of £120 per
additional point reduction in BDI score. Uncertainty in
the ICER was estimated through bootstrapping, and by
plotting the 1000 replications of mean cost and effect
differences on a cost-effectiveness plane (Figure 2). As
98% of re-samples fell within the top right-hand quad-
rant of the plane, this indicates a high likelihood of CBT
plus TAU having higher costs and better outcomes as
measured by the BDI-II. Whether this incremental
improvement in outcome represents good value for
money given the likelihood of higher service costs is a
value judgement. However, this judgement can be
informed by constructing CEACs, which show the likeli-
hood that adding CBT to TAU is more cost-effective
than TAU alone for different values placed on a unit
improvement in the BDI-II. The CEAC shows a 90%
probability that CBT will be considered cost effective if
purchasers are willing to pay up to £270 per point
reduction in BDI-II score (Figure 3). CBT has a greater
than 50% likelihood of being the most cost-effective
option only if the value placed on a unit reduction in
BDI-II score is above £115.
Discussion
CBT is significantly more costly and more effective than
TAU, and TAU plus a talking control. As discussed in
Serfaty et al (2009), the widely perceived benefits of
‘talking’ about problems were not translated into reduc-
tions in depression scores. These results confirm that
CBT is an effective psychological intervention, but it
comes at a cost. The additional costs of CBT relative to
treatment as usual (£380 at four months; £427 at 10
months) were driven by the cost of the intervention.
Whilst there was no significant difference in community
health service costs at either follow up point, patients in
the CBT group did record fewer contacts with mental
health services than patients in the other groups, sug-
gesting CBT has a substitute effect for other mental
health services.
Our primary analysis concerned the cost-effectiveness
of CBT compared with TAU at 10 months follow up.
Results showed CBT was associated with an ICER of
£120 per point reduction in BDI-II score compared to
TAU. Whether or not CBT is cost effective and repre-
sents value for money depends on how much purchasers
are willing to pay for an additional point reduction in
BDI-II score. We estimated a 90% probability that CBT
Table 5 Mean change in BDI-II score from baseline
Clinical Effectiveness CBT TAU TC CBT vs
TAU
CBT vs
TC
Reduction in BDI-II score 4
months
9.4 6.6 5.8 2.8 3.6
95% CI 7,
11
4, 9 4,
8
-0.4, 6.0 0.6, 6.4
P-value 0.084 0.010
Reduction in BDI-II score 10
months
9.7 6.2 6.0 3.6 3.5
95% CI 8,
12
4, 8 4,
9
0.7, 6.5 0.3, 6.5
P-value 0.018 0.020
Table 6 Cost-effectiveness of CBT compared to TAU at 4
and 10 months follow up
4 months follow up Mean 95% CI
Incremental cost £380 £254,
£511
Incremental effectiveness (average point reduction in
BDI)
2.8 -0.4, 6.0
Incremental cost-effectiveness (per point reduction in
BDI score)
£133
10 months follow up
Incremental cost £427 £56,
£787
Incremental effectiveness (average point reduction in
BDI)
3.6 0.7, 6.5
Incremental cost-effectiveness (per point reduction in
BDI score)
£120
Table 7 Cost-effectiveness of CBT compared to TC at 4
and 10 months follow up
4 months follow up Mean 95% CI
Incremental cost £322 £212,
£448
Incremental effectiveness (average point reduction in
BDI)
3.6 0.7, 6.5
Incremental cost-effectiveness (per point reduction in
BDI score)
£89
10 months follow up
Incremental cost £580 £280,
£930
Incremental effectiveness (average point reduction in
BDI)
3.5 0.3, 6.5
Incremental cost-effectiveness (per point reduction in
BDI score)
£167
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would be considered cost effective if purchasers are will-
ing to pay up to £270 per point reduction in BDI-II
score, and a 50% likelihood of being the most cost-effec-
tive option only if the value placed on a unit reduction
in BDI-II score is above £115. These threshold analyses
aim to indicate an upper confidence limit for cost effec-
tiveness, meaning there is a high probability that CBT
would cost no more than an additional £270 per point
reduction in BDI score. However, it is more likely the
extra cost of CBT would be closer to the mean value of
£120 per point reduction in BDI score.
Few studies have been published on the cost-effective-
ness of CBT for older people in primary care. However,
our results are comparable to those published by Bower
et al (2000) who reported no significant difference
between groups in health service costs, and also
observed more referrals to mental health services among
those receiving GP care only [13].
These results are limited by our ability to interpret
cost-effectiveness associated with changes on a depres-
sion scale, and this is an area in which more informa-
tion is needed. For example, future research may focus
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on conducting a willingness to pay study among poten-
tial purchasers. However, interpreting and comparing
ICER’s would also be made easier by expressing results
in quality adjusted life years (QALYs) using a measure
such as the Euroqol. While Euroqol data was collected
in this trial, results showed no significant difference
between groups. Although the Euroqol is often used to
determine cost-effectiveness, and may be useful in other
depressed populations [20,21], in older people it may be
too generic and lack the sensitivity required to detect
meaningful differences between groups. Alternatively,
CBT may be effective for targeting depression, but not
improving quality of life in older people. Indeed, these
findings are consistent with feedback from our thera-
pists who reported that patients did not necessarily
engage in increased activity because of associated physi-
cal problems, but their perspective about the problem
changed. In either case, these findings would suggest
that the BDI-II may be more appropriate than the EQ-
5D for evaluating the economic benefits of treatment in
this patient group.
We acknowledge that a limitation of this study is the
possibility that patient-level costs may have been influ-
enced by need-related factors, such as disease severity,
functionality and deprivation. In future studies a mea-
sure of dependency should be included, so that results
can be adjusted for any imbalances between groups.
Both the Barthel index [22], and the ECOG performance
status measure for cancer [23] are commonly used.
This cost analysis points to the importance of a ratio-
nale for the inclusion of certain costs in order to reduce
unwanted variability in cost data. Our analysis showed
inpatient admissions did not appear to be influenced by
the intervention, and were therefore excluded. Inclusion
of all possible health service costs in order to provide a
comprehensive picture of the full costs of care may
actually mask important differences in health service use
that occur in only a few areas, by adding increased
‘noise’ around costs, which are already highly variable.
Advice suggests only costs likely to differ between treat-
ment groups should be collected, as economic analysis
is primarily concerned with marginal costs [24]. Collec-
tion of resource use data can also be very expensive and
the cost of this extra information may not be justified if
only costs directly associated with providing the inter-
vention are expected to differ between groups.
Conclusions
CBT is more likely to be cost effective compared with
treatment as usual for older people presenting with
depression in primary care, assuming a willingness to
pay threshold of more than £115 per point reduction in
BDI-II score. The cost-effectiveness of CBT in this
patient group depends on how much purchasers are
willing to pay for reductions in depression scores.
Future economic evaluations of psychological interven-
tions studies should focus on marginal costs that are
expected to vary between groups as a result of an inter-
vention and also differentiate between contact with
mental health and other services.
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